CIK Cells and HDAC Inhibitors in Multiple Myeloma
AbstractMultiple myeloma is the second most common hematological malignancy. Despite all the progress made in treating multiple myeloma, it still remains an incurable disease. Patients are left with a median survival of 4–5 years. The combined treatment of multiple myeloma with histone deacetylase inhibitors and cytokine-induced killer cells provides a promising targeted treatment option for patients. This study investigated the impact of a combined treatment compared to treatment with histone deacetylase inhibitors. The experiments revealed that a treatment with histone deacetylase (HDAC) inhibitors could reduce cell viability to 59% for KMS 18 cell line and 46% for the U-266 cell line. The combined treatment led to a decrease of cell viability to 33% for KMS 18 and 27% for the U-266 cell line, thus showing a significantly better efficacy than the single treatment. View Full-Text
Share & Cite This Article
Stephan, D.; Weiher, H.; Schmidt-Wolf, I.G. CIK Cells and HDAC Inhibitors in Multiple Myeloma. Int. J. Mol. Sci. 2017, 18, 945.
Stephan D, Weiher H, Schmidt-Wolf IG. CIK Cells and HDAC Inhibitors in Multiple Myeloma. International Journal of Molecular Sciences. 2017; 18(5):945.Chicago/Turabian Style
Stephan, David; Weiher, Hans; Schmidt-Wolf, Ingo G. 2017. "CIK Cells and HDAC Inhibitors in Multiple Myeloma." Int. J. Mol. Sci. 18, no. 5: 945.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.